|
CA2375259C
(en)
*
|
1999-06-21 |
2009-04-28 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
GB0011903D0
(en)
*
|
2000-05-18 |
2000-07-05 |
Astrazeneca Ab |
Combination chemotherapy
|
|
US7019012B2
(en)
*
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
US6861422B2
(en)
*
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
|
US20050043233A1
(en)
*
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
DE10349113A1
(de)
*
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
|
US20050096332A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Boehringer Ingelheim International Gmbh |
Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
|
|
DE102004029784A1
(de)
*
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
|
DE102004033670A1
(de)
*
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
|
US7728134B2
(en)
*
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
|
US20060035903A1
(en)
*
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
|
US7759485B2
(en)
*
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
|
US20060074088A1
(en)
*
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
EP1632493A1
(de)
*
|
2004-08-25 |
2006-03-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
EP1630163A1
(de)
*
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
CZ2004964A3
(cs)
*
|
2004-09-14 |
2006-03-15 |
Pliva-Lachema A. S. |
Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
|
|
DE102004058337A1
(de)
*
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
|
ZA200706804B
(en)
|
2005-02-03 |
2008-10-29 |
Gen Hospital Corp |
Method for treating gefitinib resistant cancer
|
|
KR101354828B1
(ko)
|
2005-11-04 |
2014-02-18 |
와이어쓰 엘엘씨 |
ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
|
|
SI1948180T1
(sl)
*
|
2005-11-11 |
2013-06-28 |
Boehringer Ingelheim International Gmbh |
Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
|
|
JP5688877B2
(ja)
|
2005-11-11 |
2015-03-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌疾患の治療用キナゾリン誘導体
|
|
EP1981863B1
(en)
*
|
2006-01-26 |
2012-10-10 |
Boehringer Ingelheim International GmbH |
Process for preparing aminocrotonylamino-substituted quinazoline derivatives
|
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
|
EP2023912A2
(en)
*
|
2006-05-26 |
2009-02-18 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds in combination therapy
|
|
TW200808325A
(en)
*
|
2006-07-06 |
2008-02-16 |
Astrazeneca Ab |
Novel compounds
|
|
DK2068880T3
(da)
*
|
2006-09-18 |
2012-07-23 |
Boehringer Ingelheim Int |
Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
|
|
NZ576278A
(en)
|
2006-10-19 |
2011-12-22 |
Signal Pharm Llc |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
|
|
US8178564B2
(en)
*
|
2006-11-06 |
2012-05-15 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8173686B2
(en)
|
2006-11-06 |
2012-05-08 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8168661B2
(en)
*
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
US8168662B1
(en)
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
|
CA2672612A1
(en)
|
2006-12-14 |
2008-06-26 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as protein kinase inhibitors
|
|
US20110033528A1
(en)
*
|
2009-08-05 |
2011-02-10 |
Poniard Pharmaceuticals, Inc. |
Stabilized picoplatin oral dosage form
|
|
US20100260832A1
(en)
*
|
2007-06-27 |
2010-10-14 |
Poniard Pharmaceuticals, Inc. |
Combination therapy for ovarian cancer
|
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
|
JP2010533714A
(ja)
*
|
2007-07-16 |
2010-10-28 |
ポニアード ファーマシューティカルズ， インコーポレイテッド |
ピコプラチンのための経口製剤
|
|
EP2185559A1
(en)
*
|
2007-08-03 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Crystalline form of a dihydropteridione derivative
|
|
US8754094B2
(en)
*
|
2007-08-15 |
2014-06-17 |
The Research Foundation Of State University Of New York |
Methods for heat shock protein dependent cancer treatment
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
AU2016225895B2
(en)
*
|
2007-10-17 |
2018-02-08 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof
|
|
AU2009210656A1
(en)
*
|
2008-02-08 |
2009-08-13 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin and cetuximab to treat colorectal cancer
|
|
EP2100894A1
(en)
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
|
US20170065529A1
(en)
|
2015-09-09 |
2017-03-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical dosage form for immediate release of an indolinone derivative
|
|
UY31867A
(es)
*
|
2008-06-06 |
2010-01-29 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
|
|
HRP20180709T1
(hr)
*
|
2008-06-06 |
2018-06-15 |
Boehringer Ingelheim International Gmbh |
Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
|
|
SI2985025T1
(en)
*
|
2008-06-06 |
2018-04-30 |
Boehringer Ingelheim International Gmbh |
A pharmaceutical combination
|
|
UA107560C2
(uk)
*
|
2008-06-06 |
2015-01-26 |
|
Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
|
|
AU2015227503B2
(en)
*
|
2008-06-06 |
2017-02-23 |
Boehringer Ingelheim International Gmbh |
Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
|
|
CA2725598C
(en)
|
2008-06-17 |
2013-10-08 |
Wyeth Llc |
Antineoplastic combinations containing hki-272 and vinorelbine
|
|
MX2011000026A
(es)
|
2008-06-23 |
2011-02-24 |
Vertex Pharma |
Inhibidores de proteina cinasas.
|
|
MX2011001318A
(es)
|
2008-08-04 |
2011-03-04 |
Wyeth Llc |
Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
|
|
CA2744031A1
(en)
*
|
2008-11-21 |
2010-05-27 |
Isis Pharmaceuticals, Inc. |
Anticancer combination comprising docetaxel and an antisense oligonucleotide
|
|
JPWO2010064422A1
(ja)
*
|
2008-12-02 |
2012-05-10 |
静岡県公立大学法人 |
ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法
|
|
EP2416774B1
(en)
|
2009-04-06 |
2015-11-04 |
Wyeth LLC |
Treatment regimen utilizing neratinib for breast cancer
|
|
KR101224468B1
(ko)
*
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
HUE044629T2
(hu)
|
2009-07-06 |
2019-11-28 |
Boehringer Ingelheim Int |
Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
|
|
ES2543280T3
(es)
|
2009-08-10 |
2015-08-17 |
Board Of Regents, The University Of Texas System |
Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
|
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
|
CN102020643A
(zh)
|
2009-09-22 |
2011-04-20 |
上海恒瑞医药有限公司 |
二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
|
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
|
PT2496567T
(pt)
|
2009-11-05 |
2017-11-15 |
Rhizen Pharmaceuticals S A |
Novos moduladores de quinase benzopiran
|
|
PH12012501581A1
(en)
*
|
2010-02-03 |
2012-10-22 |
Signal Pharm Llc |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
US20120329803A1
(en)
*
|
2010-02-17 |
2012-12-27 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones, method for production and use thereof
|
|
MX373121B
(es)
|
2010-05-14 |
2020-04-30 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
CA2799381A1
(en)
|
2010-05-14 |
2011-11-17 |
Dana-Farber Cancer Institute, Inc. |
Male contraceptive compositions and methods of use
|
|
WO2011140828A1
(en)
*
|
2010-05-14 |
2011-11-17 |
The University Of Hong Kong |
Gep antibody and uses thereof
|
|
US8981083B2
(en)
|
2010-05-14 |
2015-03-17 |
Dana Farber Cancer Institute, Inc. |
Compositions and methods for treating neoplasia, inflammatory disease and other disorders
|
|
EP2575815A4
(en)
|
2010-06-04 |
2013-12-25 |
Albany Molecular Res Inc |
GLYCIN TRANSPORTER 1 INHIBITORS, METHODS OF MAKING THE SAME, AND USES THEREOF
|
|
PT2608792T
(pt)
|
2010-08-26 |
2018-01-15 |
Boehringer Ingelheim Int |
Métodos de administração de um inibidor de egfr
|
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
|
WO2012079075A1
(en)
|
2010-12-10 |
2012-06-14 |
Concert Pharmaceuticals, Inc. |
Deuterated phthalimide derivatives
|
|
WO2012148548A1
(en)
|
2011-02-25 |
2012-11-01 |
Takeda Pharmaceutical Company Limited |
N-substituted oxazinopteridines and oxazinopteridinones
|
|
RS58326B1
(sr)
|
2011-05-04 |
2019-03-29 |
Rhizen Pharmaceuticals S A |
Nova jedinjenja kao modulatori proteinskih kinaza
|
|
US20130131069A1
(en)
*
|
2011-05-13 |
2013-05-23 |
Boehringer Ingelheim International Gmbh |
Method for treatment of solid malignancies including advanced or metastatic solid malignancies
|
|
US8828391B2
(en)
|
2011-05-17 |
2014-09-09 |
Boehringer Ingelheim International Gmbh |
Method for EGFR directed combination treatment of non-small cell lung cancer
|
|
US9370535B2
(en)
*
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
|
WO2013130849A1
(en)
|
2012-02-29 |
2013-09-06 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
WO2013159026A1
(en)
|
2012-04-20 |
2013-10-24 |
Concert Pharmaceuticals, Inc. |
Deuterated rigosertib
|
|
KR101988079B1
(ko)
|
2012-07-04 |
2019-06-11 |
리젠 파마슈티컬스 소시에떼 아노님 |
선택적 pi3k 델타 억제제
|
|
EP2875020B1
(en)
|
2012-07-19 |
2017-09-06 |
Boehringer Ingelheim International GmbH |
Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
|
|
CA2882292C
(en)
*
|
2012-08-13 |
2023-10-17 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
EP2922838B1
(en)
|
2012-10-22 |
2018-03-14 |
Concert Pharmaceuticals Inc. |
Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
|
|
WO2014110322A2
(en)
|
2013-01-11 |
2014-07-17 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
MX368286B
(es)
|
2013-04-17 |
2019-09-27 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
|
|
HK1221150A1
(zh)
|
2013-04-17 |
2017-05-26 |
西格诺药品有限公司 |
用二氢吡嗪并-吡嗪类对癌症的治疗
|
|
MX393164B
(es)
|
2013-04-17 |
2025-03-21 |
Signal Pharm Llc |
Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona.
|
|
CN105339008A
(zh)
|
2013-04-17 |
2016-02-17 |
西格诺药品有限公司 |
用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
|
|
EP2986321A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
|
BR112015026257B1
(pt)
|
2013-04-17 |
2022-12-20 |
Signal Pharmaceuticals, Llc |
Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
|
|
JP6382945B2
(ja)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ，エルエルシー |
ジヒドロピラジノ−ピラジンによる癌治療
|
|
NZ629486A
(en)
|
2013-05-29 |
2017-11-24 |
Signal Pharm Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
BR112016001457A2
(pt)
|
2013-07-25 |
2017-08-29 |
Dana Farber Cancer Inst Inc |
Inibidores de fatores de transcrição e usos dos mesmos
|
|
CA2919296A1
(en)
*
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii
|
|
CN105407893A
(zh)
*
|
2013-07-26 |
2016-03-16 |
勃林格殷格翰国际有限公司 |
伏拉塞替与地西他滨组合用于急性骨髓性白血病和骨髓增生异常综合征的治疗ii
|
|
WO2015011236A1
(en)
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Treatment of myelodysplastic syndrome
|
|
KR20160072261A
(ko)
|
2013-11-08 |
2016-06-22 |
다나-파버 캔서 인스티튜트 인크. |
브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
AR099052A1
(es)
|
2014-01-09 |
2016-06-29 |
Takeda Pharmaceuticals Co |
Derivados de azaindol
|
|
KR20160111036A
(ko)
|
2014-01-31 |
2016-09-23 |
다나-파버 캔서 인스티튜트 인크. |
디아제판 유도체 및 그의 용도
|
|
MX2016009974A
(es)
|
2014-01-31 |
2016-10-31 |
Dana Farber Cancer Inst Inc |
Derivados de diaminopirimidina bencensulfona y sus usos.
|
|
US20160347750A1
(en)
*
|
2014-01-31 |
2016-12-01 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
|
WO2015117087A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
RU2722179C2
(ru)
|
2014-02-28 |
2020-05-28 |
Тэнша Терапеутикс, Инк. |
Лечение состояний, ассоциированных с гиперинсулинемией
|
|
EP3131551A4
(en)
|
2014-04-16 |
2017-09-20 |
Signal Pharmaceuticals, LLC |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
WO2016022970A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
|
EP3177626A4
(en)
|
2014-08-08 |
2017-12-27 |
Dana Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
|
UA122130C2
(uk)
|
2014-10-27 |
2020-09-25 |
Тенша Терапеутікс, Інк. |
Інгібітори бромодомену
|
|
NZ731789A
(en)
|
2014-10-30 |
2019-04-26 |
Kangpu Biopharmaceuticals Ltd |
Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
|
|
CN106279173A
(zh)
*
|
2015-05-29 |
2017-01-04 |
华东理工大学 |
蝶啶酮衍生物作为egfr抑制剂的应用
|
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
US11306105B2
(en)
|
2015-09-11 |
2022-04-19 |
Dana-Farber Cancer Institute, Inc. |
Cyano thienotriazolodiazepines and uses thereof
|
|
JP2018526424A
(ja)
|
2015-09-11 |
2018-09-13 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
|
|
CR20180336A
(es)
|
2015-11-25 |
2018-08-06 |
Dana Farber Cancer Inst Inc |
Inhibidores de bromodominio bivalentes y usos de los mismos
|
|
DE102017005089A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
|
|
DE102017005091A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
|
|
CN106831765B
(zh)
*
|
2016-12-28 |
2018-12-14 |
郑州大学 |
2-(2,6-二氰基苯基)咪唑并[1,2-α]吡啶类化合物及其制备方法
|
|
DK3590924T3
(da)
|
2017-02-28 |
2022-01-03 |
Kangpu Biopharmaceuticals Inc |
Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf
|
|
EP4234035A3
(en)
|
2017-05-16 |
2023-11-15 |
Ability Pharmaceuticals S.A. |
A pharmaceutical combination for the treatment of a cancer
|
|
IL271491B2
(en)
|
2017-06-22 |
2023-09-01 |
Celgene Corp |
Treatment of carcinoma of the liver characterized by hepatitis b virus infection
|
|
CN109776788B
(zh)
*
|
2017-11-14 |
2021-07-30 |
博瑞生物医药（苏州）股份有限公司 |
叶酸受体靶向多臂偶联物
|
|
US20210038602A1
(en)
|
2018-01-25 |
2021-02-11 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia
|
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
WO2020033823A1
(en)
*
|
2018-08-10 |
2020-02-13 |
Yale University |
Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
|
|
CN111285850B
(zh)
|
2018-12-06 |
2022-04-22 |
中国科学院上海药物研究所 |
一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
|
|
IL288024B2
(en)
|
2019-05-14 |
2025-12-01 |
Provention Bio Inc |
Methods and compositions for preventing type
|
|
CN110156700A
(zh)
*
|
2019-06-05 |
2019-08-23 |
鲁南制药集团股份有限公司 |
吉非替尼与水杨酸共晶体
|
|
JP7689964B2
(ja)
|
2019-12-13 |
2025-06-09 |
インスピルナ，インコーポレーテッド |
金属塩及びその使用
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
MX2023013851A
(es)
|
2021-05-24 |
2023-12-08 |
Provention Bio Inc |
Metodos para el tratamiento de diabetes tipo 1.
|
|
WO2025228947A1
(en)
|
2024-04-30 |
2025-11-06 |
Crossfire Oncology B.V. |
Bifunctional compounds capable of inducing degradation of polo-like kinase1
|